What is your approach to first line systemic therapy in metastatic PD-L1 positive cervical cancer?

Without question, pembrolizumab should be included in first line systemic therapy and not reserved as a second line option. The transformative results from KEYNOTE-826 led to FDA approval on 10/13/21 of pembrolizumab in combination with platinum and taxane therapy (+ bevacizumab) for first line trea...

Also, radiation for primary site depending on symptoms. In addition, look for other disease sites that may require individual attention.